These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 40027)

  • 41. Synthesis, resolution, and renal vasodilation activity of novel DA1 agonists: 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline derivatives.
    Anan H; Tanaka A; Tsuzuki R; Yokota M; Yatsu T; Honda K; Asano M; Fujita S; Furuya T; Fujikura T
    Chem Pharm Bull (Tokyo); 1991 Nov; 39(11):2910-4. PubMed ID: 1839245
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A study of the conformational requirements for direct adrenergic stimulation.
    Gray AP; Reit E; Ackerly JA; Hava M
    J Med Chem; 1973 Sep; 16(9):1023-7. PubMed ID: 4147657
    [No Abstract]   [Full Text] [Related]  

  • 43. The effects of dopexamine on the cardiovascular system of the dog.
    Brown RA; Farmer JB; Hall JC; Humphries RG; O'Connor SE; Smith GW
    Br J Pharmacol; 1985 Jul; 85(3):609-19. PubMed ID: 4027482
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of the effects of the novel inotropic agent, ibopamine, with epinine, dopamine and fenoldopam on renal vascular dopamine receptors in the anesthetized dog.
    Nichols AJ; Smith JM; Shebuski RJ; Ruffolo RR
    J Pharmacol Exp Ther; 1987 Aug; 242(2):573-8. PubMed ID: 2886644
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 5,7-Dihydroxy-2-aminotetralin derivatives: synthesis and assessment of dopaminergic and adrenergic actions.
    Cannon JG; Brubaker AN; Long JP; Flynn JR; Verimer T; Harnirattisai P; Costall B; Naylor RJ; Nohria V
    J Med Chem; 1981 Feb; 24(2):149-53. PubMed ID: 7205882
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative systemic and regional hemodynamic effects of dopamine and dobutamine.
    Robie NW; Goldberg LI
    Am Heart J; 1975 Sep; 90(3):340-5. PubMed ID: 240265
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacological actions of dopamine sulfoconjugate on cardiovascular system.
    Takeo S; Tanonaka K; Anan M; Hiraga S
    Arch Int Pharmacodyn Ther; 1987 Sep; 289(1):60-71. PubMed ID: 3435206
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Circulatory activity of dopamine-dipeptide compounds.
    Krause W; Oehme P; Barth A; Neubert K
    Biomed Biochim Acta; 1988; 47(9):895-900. PubMed ID: 3248125
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dopamine vascular actions of N-substituted derivatives of 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene (ADTN).
    Kohli JD; Goldberg LI; Nichols DE
    Eur J Pharmacol; 1979 Jun; 56(1-2):39-44. PubMed ID: 467513
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular and renal action of dopaminergic prodrugs.
    Casagrande C; Merlo L; Ferrini R; Miragoli G; Semeraro C
    J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S40-59. PubMed ID: 2483441
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Conformationally restricted congeners of dopamine derived from 2-aminoindan.
    Cannon JG; Perez JA; Bhatnagar RK; Long JP; Sharabi FM
    J Med Chem; 1982 Dec; 25(12):1442-6. PubMed ID: 7154005
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Specific dopamine D-1 and DA1 properties of 4-(mono- and -dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline and its tetrahydrothieno[2,3-c]pyridine analogue.
    Riggs RM; Nichols DE; Foreman MM; Truex LL; Glock D; Kohli JD
    J Med Chem; 1987 Aug; 30(8):1454-8. PubMed ID: 2956423
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adrenergic agents. 4. Substituted phenoxypropanolamine derivatives as potential beta-adrenergic agonists.
    Kaiser C; Jen T; Garvey E; Bowen WD; Colella DF; Wardel JR
    J Med Chem; 1977 May; 20(5):687-92. PubMed ID: 16136
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of dopamine infusion on cardiac and renal blood flows in dogs.
    Furukawa S; Nagashima Y; Hoshi K; Hirao H; Tanaka R; Maruo K; Yamane Y
    J Vet Med Sci; 2002 Jan; 64(1):41-4. PubMed ID: 11853144
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacological studies of 3-[bis(3,3-diphenylpropyl)-amino]-propan-1-ol hydrochloride, (PF-244), a new cerebral vasodilator.
    Kadokawa T; Fujitani B; Kuwashima J; Hatano N; Shimizu M
    Arzneimittelforschung; 1975 Apr; 25(4):632-8. PubMed ID: 1174078
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis, conformation, and dopaminergic activity of 5,6-ethano-bridged derivatives of selective dopaminergic 3-benzazepines.
    Weinstock J; Oh HJ; DeBrosse CW; Eggleston DS; Wise M; Flaim KE; Gessner GW; Sawyer JL; Kaiser C
    J Med Chem; 1987 Aug; 30(8):1303-8. PubMed ID: 2886663
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Conformationally defined adrenergic agents. 5. Resolution, absolute configuration, and pharmacological characterization of the enantiomers of 2-(5,6-dihydroxy-1,2,3,4-tetrahydro-1-naphthyl)imidazoline: a potent agonist at alpha-adrenoceptors.
    DeBernardis JF; Kerkman DJ; Arendsen DL; Buckner SA; Kyncl JJ; Hancock AA
    J Med Chem; 1987 Jun; 30(6):1011-7. PubMed ID: 2884313
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inotropic mechanisms of dopexamine hydrochloride in horses.
    Muir WW
    Am J Vet Res; 1992 Aug; 53(8):1343-6. PubMed ID: 1354950
    [TBL] [Abstract][Full Text] [Related]  

  • 59. FPL 63012AR: a potent D1-receptor agonist.
    Smith GW; Farmer JB; Ince F; Matu K; Mitchell PD; Naya I; Springthorpe B
    Br J Pharmacol; 1990 Jun; 100(2):295-300. PubMed ID: 1974159
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of the effects of dopamine-1 and dopamine-2 receptor agonists on coronary flow.
    Zhao RR; Wang PH; Zhang WF; Fennell WH
    Methods Find Exp Clin Pharmacol; 1992; 14(1):5-11. PubMed ID: 1352371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.